• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

尼伏单抗治疗后发生硬化性胆管炎。

Sclerosing cholangitis in a patient treated with nivolumab.

机构信息

Gastroenterology, NHS Greater Glasgow and Clyde, Glasgow, UK

Clinical Oncology, Beatson West of Scotland Cancer Centre, Glasgow, UK.

出版信息

BMJ Case Rep. 2021 May 28;14(5):e241700. doi: 10.1136/bcr-2021-241700.

DOI:10.1136/bcr-2021-241700
PMID:34049893
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8166617/
Abstract

A 69-year-old retired miner with stage 4 non-small-cell lung cancer presented with a 2-month history of obstructive liver function tests following nivolumab immunotherapy. His case had not responded to high dose prednisolone or mycophenolate and he was admitted for investigation. MR cholangiopancreatography demonstrated areas of intrahepatic biliary tree beading and stricturing, in keeping with sclerosing cholangitis. Prednisolone and mycophenolate were stopped and ursodeoxycholic acid commenced with subsequent partial improvement of the patient's liver function tests.

摘要

一位 69 岁的退休矿工患有 4 期非小细胞肺癌,在接受 nivolumab 免疫治疗后出现了 2 个月的阻塞性肝功能检查病史。他的病情对大剂量泼尼松龙或吗替麦考酚酯没有反应,因此入院进行检查。磁共振胆胰管成像显示肝内胆管呈串珠状和狭窄,符合硬化性胆管炎。停止使用泼尼松龙和吗替麦考酚酯,并开始使用熊去氧胆酸,随后患者的肝功能检查有所部分改善。

相似文献

1
Sclerosing cholangitis in a patient treated with nivolumab.尼伏单抗治疗后发生硬化性胆管炎。
BMJ Case Rep. 2021 May 28;14(5):e241700. doi: 10.1136/bcr-2021-241700.
2
A case with life-threatening secondary sclerosing cholangitis caused by nivolumab.由纳武利尤单抗引起的危及生命的继发性硬化性胆管炎病例。
Clin J Gastroenterol. 2021 Feb;14(1):283-287. doi: 10.1007/s12328-020-01287-1. Epub 2020 Nov 16.
3
A case report on severe nivolumab-induced adverse events similar to primary sclerosing cholangitis refractory to immunosuppressive therapy.一例严重 nivolumab 诱导的不良反应病例报告,类似于原发性硬化性胆管炎,对免疫抑制治疗难治。
Medicine (Baltimore). 2021 Jun 11;100(23):e25774. doi: 10.1097/MD.0000000000025774.
4
Case of nivolumab-induced sclerosing cholangitis: lessons from long-term follow-up.尼伏单抗诱导的硬化性胆管炎病例:长期随访的经验教训。
BMJ Open Gastroenterol. 2020 Sep;7(1). doi: 10.1136/bmjgast-2020-000487.
5
Pembrolizumab-induced sclerosing cholangitis in a lung adenocarcinoma patient with a remarkable response to chemotherapy: a case report.帕博利珠单抗致肺腺癌化疗后显著缓解患者硬化性胆管炎 1 例报告
Clin J Gastroenterol. 2020 Dec;13(6):1310-1314. doi: 10.1007/s12328-020-01178-5. Epub 2020 Jul 8.
6
Development of mild drug-induced sclerosing cholangitis after discontinuation of nivolumab.停用纳武单抗后发生轻度药物性硬化性胆管炎。
Eur J Cancer. 2019 Jan;107:93-96. doi: 10.1016/j.ejca.2018.11.021. Epub 2018 Dec 13.
7
A prospective, randomized-controlled pilot study of ursodeoxycholic acid combined with mycophenolate mofetil in the treatment of primary sclerosing cholangitis.一项关于熊去氧胆酸联合霉酚酸酯治疗原发性硬化性胆管炎的前瞻性、随机对照试验研究。
Aliment Pharmacol Ther. 2004 Nov 1;20(9):943-9. doi: 10.1111/j.1365-2036.2004.02214.x.
8
Atezolizumab-induced Sclerosing Cholangitis in a patient with lung cancer: A case report.阿特珠单抗引起的肺癌患者硬化性胆管炎:病例报告。
Cancer Treat Res Commun. 2021;26:100270. doi: 10.1016/j.ctarc.2020.100270. Epub 2020 Dec 10.
9
Programmed cell death-1 inhibitor-related sclerosing cholangitis: A systematic review.程序性细胞死亡蛋白-1 抑制剂相关硬化性胆管炎:系统评价。
World J Gastroenterol. 2020 Jan 21;26(3):353-365. doi: 10.3748/wjg.v26.i3.353.
10
Efficacy and Safety of Chemotherapy Following Anti-PD-1 Antibody Therapy for Gastric Cancer: A Case of Sclerosing Cholangitis.抗PD-1抗体治疗后胃癌化疗的疗效与安全性:1例硬化性胆管炎病例
Intern Med. 2019 May 1;58(9):1263-1266. doi: 10.2169/internalmedicine.1981-18. Epub 2019 Jan 10.

引用本文的文献

1
Immunoglobulin G4 associated autoimmune cholangitis and pancreatitis following the administration of nivolumab: A case report.纳武单抗治疗后发生的免疫球蛋白G4相关性自身免疫性胆管炎和胰腺炎:一例报告
World J Clin Cases. 2022 Jul 16;10(20):7124-7129. doi: 10.12998/wjcc.v10.i20.7124.
2
Clinical Characteristics of ICI-Related Pancreatitis and Cholangitis Including Radiographic and Endoscopic Findings.免疫检查点抑制剂相关胰腺炎和胆管炎的临床特征,包括影像学和内镜检查结果
Healthcare (Basel). 2022 Apr 20;10(5):763. doi: 10.3390/healthcare10050763.

本文引用的文献

1
Histologic patterns of liver injury induced by anti-PD-1 therapy.抗程序性死亡蛋白1(PD-1)疗法诱导的肝损伤的组织学模式。
Gastroenterol Rep (Oxf). 2019 Sep 20;8(1):50-55. doi: 10.1093/gastro/goz044. eCollection 2020 Feb.
2
Pembrolizumab-induced secondary sclerosing cholangitis in a non-small cell lung cancer patient.帕博利珠单抗诱发的非小细胞肺癌患者继发性硬化性胆管炎
Respirol Case Rep. 2020 Apr 10;8(5):e00560. doi: 10.1002/rcr2.560. eCollection 2020 Jul.
3
Primary Sclerosing Cholangitis: Epidemiology, Genetics, Diagnosis, and Current Management.原发性硬化性胆管炎:流行病学、遗传学、诊断及当前治疗方法
Clin Liver Dis (Hoboken). 2020 Apr 4;15(3):125-128. doi: 10.1002/cld.902. eCollection 2020 Mar.
4
Programmed cell death-1 inhibitor-related sclerosing cholangitis: A systematic review.程序性细胞死亡蛋白-1 抑制剂相关硬化性胆管炎:系统评价。
World J Gastroenterol. 2020 Jan 21;26(3):353-365. doi: 10.3748/wjg.v26.i3.353.
5
Diagnosis and Management of Autoimmune Hepatitis in Adults and Children: 2019 Practice Guidance and Guidelines From the American Association for the Study of Liver Diseases.成人和儿童自身免疫性肝炎的诊断与管理:美国肝病研究协会2019年实践指南与规范
Hepatology. 2020 Aug;72(2):671-722. doi: 10.1002/hep.31065. Epub 2020 May 12.
6
Nivolumab-induced cholangitis in patients with non-small cell lung cancer: Case series and a review of literature.纳武利尤单抗诱发非小细胞肺癌患者胆管炎:病例系列及文献综述
Mol Clin Oncol. 2019 Nov;11(5):439-446. doi: 10.3892/mco.2019.1923. Epub 2019 Sep 18.
7
Immune-related adverse reactions in the hepatobiliary system: second-generation check-point inhibitors highlight diverse histological changes.肝胆系统免疫相关不良反应:第二代检查点抑制剂凸显多样化的组织学改变。
Histopathology. 2020 Feb;76(3):470-480. doi: 10.1111/his.14000. Epub 2019 Dec 1.
8
British Society of Gastroenterology and UK-PSC guidelines for the diagnosis and management of primary sclerosing cholangitis.英国胃肠病学会和英国PSC 指南:原发性硬化性胆管炎的诊断和管理。
Gut. 2019 Aug;68(8):1356-1378. doi: 10.1136/gutjnl-2018-317993. Epub 2019 Jun 1.
9
Secondary sclerosing cholangitis with hemobilia induced by pembrolizumab: Case report and review of published work.帕博利珠单抗诱导的继发性硬化性胆管炎伴胆道出血:病例报告及已发表文献综述
Hepatol Res. 2019 Aug;49(8):950-956. doi: 10.1111/hepr.13329. Epub 2019 Apr 10.
10
Efficacy and Safety of Chemotherapy Following Anti-PD-1 Antibody Therapy for Gastric Cancer: A Case of Sclerosing Cholangitis.抗PD-1抗体治疗后胃癌化疗的疗效与安全性:1例硬化性胆管炎病例
Intern Med. 2019 May 1;58(9):1263-1266. doi: 10.2169/internalmedicine.1981-18. Epub 2019 Jan 10.